Showing 3791-3800 of 8096 results for "".
- Galderma's Cetaphil Celebrates 65 Yearshttps://practicaldermatology.com/news/20120711-galdermas_cetaphil_celebarates_65_years/2459775/Galderma's Cetaphil Gentle Skin Cleanser is celebrating 65 years on the market. Introduced in 1947 as Cetaphil Cleansing Lotion, it was initially developed by a pharmacist for use as a compounding base. By the 1960s, the product was so popular t
- Efficacy Data for LaViv Now Publishedhttps://practicaldermatology.com/news/20120418-efficacy_data_for_laviv_now_published/2459822/Data demonstrating that LaViv (azficel-T, Fibrocell Science, Inc.) is effective for the aesthetic improvement of moderate to severe smile lines are now published online in Dermatologic Surgery. The combined results of two identically-designed, Phase III, multi-
- Onset Launches Aurstat Kithttps://practicaldermatology.com/news/20120302-onset_launches_aurstat_kit/2459855/The Aurstat Kit (Onset Dermatologics) containing Aurstat Skin and Wound Hydrogel and HylatopicPlus Cream is now available. Aurstat is an easy to use topical formulation, the company says. HylatopicPlus is a ceramide-rich, non-steroidal prescription t
- Clascoterone 5% Solution Achieves Hair Regrowth in Large AGA Studyhttps://practicaldermatology.com/news/clascoterone-5-solution-acheives-hair-regrowth-in-large-aga-study/2484730/Cosmo Pharmaceuticals N.V. has reported phase 3 results from its two pivotal trials—Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805)—evaluating clascoterone 5% topical solution for male androgenetic alopecia (AGA). According t
- AB Chopra Epigenetics Launches With Plan to Revolutionize Longevityhttps://practicaldermatology.com/news/AB-Chopra-Epigenetics-Launches-With-Plan-Revolutionize-Longevity/2475124/Charles Rosier, co-founder of the Augustinus Bader skincare and biotech company, and Deepak Chopra, MD, announced the launch of AB Chopra Epigenetics, a revolutionary longevity platform that merges advanced artificial intelligence, epigenetic science, and consciousness-based healing to redefine t
- Acne Vaccine Could Be 'Revolutionary,' Dr. Stein Gold Sayshttps://practicaldermatology.com/news/Acne-Vaccine-Could-Be-Revolutionary-Dr-Stein-Gold-Says/2471165/The next major breakthrough in acne could be a “revolutionary” vaccine targeting the strain of c. Acnes bacteria that produces the Hyl-A enzyme, Linda Stein Gold, MD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “It is still in early clinical trials, but I t
- Hidradenitis Suppurativa Genetics Linked to Cardiometabolic Riskhttps://practicaldermatology.com/news/hidradenitis-suppurativa-genetics-linked-to-cardiometabolic-risk/2471117/A high polygenic risk score (PRS) for hidradenitis suppurativa (HS) is linked to an increased risk of coronary artery disease (CAD) and diabetes, according to a new analysis of UK Biobank data. Study researchers included 391,481 individuals of European ancestry with data in UK Biobank in t
- Analysis: COX1 Genotype Determines Fish Oil’s Efficacy Against ADhttps://practicaldermatology.com/news/analysis-cox1-genotype-determines-fish-oils-efficacy-against-ad/2467997/A secondary analysis of a randomized clinical trial indicated prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation may reduce the risk of childhood atopic dermatitis (AD) in a genotype-specific manner. Researchers for the analysis reported that mothers carrying t
- Fish Residues Could Supply Collagenhttps://practicaldermatology.com/news/fish-residues-could-supply-collagen/2462980/Researchers in Norway believe fish residues can supplement current sources of raw materials for collagen and gelatin, according to a Phys.org article. A project called SUPREME, headed by the Norwegian science institute SINTEF Ocean in collaboration with Norwegian university NTNU and the T
- Lilly Resubmits BLA for Lebrikizumabhttps://practicaldermatology.com/news/lilly-resubmits-bla-lebrikizumab/2462907/Eli Lilly and Company announced as part of its 2024 first-quarter financial report that it as resubmitted the biologic license application (BLA) for lebrikizumab to the U.S. Food and Drug Administration for the treatment of people 12 and older with moderate-to-severe atopic dermatitis (eczema), t